A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Phase 3
450
about 6.9 years
18+
50 sites in AZ, CA, CO +23
About this study
This trial is testing a treatment called anitocabtagene autoleucel compared to standard therapy for people with relapsed or refractory multiple myeloma. The goal is to see if the new treatment improves outcomes.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Anitocabtagene Autoleucel
- 2.Take Bortezomib
- 3.Take Carfilzomib
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
bortezomib, carfilzomib, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), daratumumab, dexamethasone, fludarabine, pomalidomide
injection (Injection), infusion, injection, ocular, oral (Oral Capsule)
Primary: Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 Months, Progression-Free Survival (PFS)
Secondary: CR Rate (CR/ Stringent Complete Response (sCR)), Change From Baseline in the EORTC - Multiple Myeloma Module (EORTC QLQ-MY20) Score, Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score, Change From Baseline in the European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Score, Duration of Response (DOR), MRD-negative CR/sCR, Overall Response Rate (ORR), Overall survival (OS)
Oncology